Brought to you by 
Series B round totals $75mm for Ovid Therapeutics
15 Sep 2017
Executive Summary
Fidelity Management and Research Co. led a $75mm Series B financing for Ovid Therapeutics Inc. (orphan brain diseases). Other new backers included Cowen Private Investments, Sanofi-Genzyme BioVentures, Tekla Capital Management, Sphera Global Healthcare Fund, Jennison Associates, Redmile Group, Cormorant Asset Management, and undisclosed blue chip mutual funds and life science investors. Returning shareholders including DoubleLine Equity Healthcare Fund also joined. Cowen & Co. was the placement agent.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B round totals $75mm for Ovid Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice